DRG Epidemiology’s coverage of scleroderma (systemic sclerosis) (SSc) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and the diagnosed prevalence of SSc for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting diagnosed incident and diagnosed prevalent patient populations, we estimate the number of drug-treatment opportunities in the major mature pharmaceutical markets.
DRG Epidemiology’s SSc forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
In total, DRG Epidemiology forecasts seven SSc patient populations, as follows:
Note: Coverage may vary by country.